SELLAS Life Sciences: Phase 3 Success for Cancer Vaccine GPS Drives Price Target to $40 by Maxim!
Reading Time: 2 minutes
The cancer vaccine GPS from SELLAS Life Sciences (SLS) achieved an extension of overall survival in the Phase 3 clinical study for acute myeloid leukemia (AML). Maxim analyst Jason McCarthy confirms the buy recommendation and raises the price target from $30 to $40. Management is preparing the regulatory application and announces a capital measure of $150 million for financing. Business Model and Targeted Growth Trends SELLAS Life Sciences (SLS) is a biopharmaceutical company in late-stage clinical development. The operational focus is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

